Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling

International Journal of Cancer

Volumn 129, Issue 12, 2011, Pages 2935-2944

  Hombach, Andreas A ^a   Abken, Hinrich ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

4 1BB; CD28; cellular activation; chimeric antigen receptor; gene therapy; OX40; T lymphocytes

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD134 ANTIGEN; CD137 ANTIGEN; CD28 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; L SELECTIN; LYMPHOCYTE ANTIGEN RECEPTOR; RECOMBINANT DNA;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; EFFECTOR CELL; EMBRYO; MEMORY T LYMPHOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CANCER TRANSPLANTATION; CYTOTOXICITY; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; METHODOLOGY; NEOPLASM; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD28; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DNA, RECOMBINANT; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, OX40; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84855186143     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25960     Document Type: Article

References (34)

1. Eshhar Z, Waks T, Gross G, Schindler DG,. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993; 90: 720-4. (Pubitemid 23028937)
2. Berry LJ, Moeller M, Darcy PK,. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells. Tissue Antigens 2009; 74: 277-289.
3. Sadelain M, Brentjens R, Rivière I,. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21: 215-23.
4. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ, Gopal AK, Pagel JM, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008; 112: 2261-71.
5. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006; 12: 6106-15. (Pubitemid 44703776)
6. Lamers CHJ, Sleijfer S, Vulto AG, Kruit WHJ, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E,. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006; 24: e20-22.
7. Finney HM, Akbar AN, Lawson ADG,. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 2004; 172: 104-13. (Pubitemid 38020461)
8. Bridgeman JS, Hawkins RE, Hombach AA, Abken H, Gilham DE,. Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther 2010; 10: 77-90.
9. Hombach A, Sent D, Schneider C, Heuser C, Koch D, Pohl C, Seliger B, Abken H,. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Cancer Res 2001; 61: 1976-82. (Pubitemid 32692016)
10. Sadelain M, Rivière I, Brentjens R,. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003; 3: 35-45. (Pubitemid 37328885)
11. Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M,. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 2002; 20: 70-5. (Pubitemid 34044918)
12. Watts TH,. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005; 23: 23-68. (Pubitemid 40563164)
13. Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK,. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005; 12: 933-41. (Pubitemid 41614489)
14. Abken H, Hombach A, Heuser C, Kronfeld K, Seliger B,. Tuning tumor-specific T-cell activation: a matter of costimulation? Trends Immunol 2002; 23: 240-5. (Pubitemid 34499560)
15. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M,. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010; 18: 666-8.
16. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA,. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18: 843-51.
17. Heslop HE,. Safer CARS. Mol Ther 2010; 18: 661-2.
18. Weijtens ME, Willemsen RA, Hart EH, Bolhuis RL,. A retroviral vector system "STITCH" in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Ther 1998; 5: 1195-03.
19. Kaulen H, Seemann G, Bosslet K, Schwaeble W, Dippold W,. Humanized anti-carcinoembryonic antigen antibody: strategies to enhance human tumor cell killing. Year Immunol 1993; 7: 106-9.
20. Hombach A, Schlimper C, Sievers E, Frank S, Schild HH, Sauerbruch T, Schmidt-Wolf IGH, Abken H,. A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3zeta-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells. Gut 2006; 55: 1156-64. (Pubitemid 44085685)
21. Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, Seliger B, Abken H,. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 2001; 167: 6123-31. (Pubitemid 33081538)
22. Jost LM, Kirkwood JM, Whiteside TL,. Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J Immunol Methods 1992; 147: 153-5.
23. Hombach A, Heuser C, Marquardt T, Wieczarkowiecz A, Groneck V, Pohl C, Abken H,. CD4+ T cells engrafted with a recombinant immunoreceptor efficiently lyse target cells in a MHC antigen- and Fas-independent fashion. J Immunol 2001; 167: 1090-6. (Pubitemid 32660869)
24. Masopust D, Vezys V, Marzo AL, Lefrançois L,. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001; 291: 2413-7. (Pubitemid 32231804)
25. Lefrançois L,. Development, trafficking, and function of memory T-cell subsets. Immunol Rev 2006; 211: 93-103. (Pubitemid 43882964)
26. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, Carroll RG, Riley JL, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA 2009; 106: 3360-5.
27. Lee S, Park Y, Song A, Cheroutre H, Kwon BS, Croft M,. Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses. J Immunol 2006; 177: 4464-72. (Pubitemid 44469776)
28. Pardee AD, Wesa AK, Storkus WJ,. Integrating costimulatory agonists to optimize immune-based cancer therapies. Immunotherapy 2009; 1: 249-64.
29. Cooper D, Bansal-Pakala P, Croft M,. 4-1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity. Eur J Immunol 2002; 32: 521-9. (Pubitemid 34173343)
30. Cannons JL, Lau P, Ghumman B, DeBenedette MA, Yagita H, Okumura K, Watts TH,. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol 2001; 167: 1313-24. (Pubitemid 32703127)
31. Till BG, Press OW,. Treatment of lymphoma with adoptively transferred T cells. Expert Opin Biol Ther 2009; 9: 1407-25.
32. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and anti-tumor activity in individuals with neuroblastoma. Nat Med 2008; 14: 1264-70.
33. Chmielewski M, Hombach A, Heuser C, Adams GP, Abken H,. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol 2004; 173: 7647-53. (Pubitemid 39628207)
34. Chmielewski M, Hombach AA, Abken H,. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack. Gene Ther 2011; 18: 62-72.